Insight
Danish Clinical trials on the rise
Denmark continues to solidify its position as a leader in clinical trials with a report from The Danish Association of the Pharmaceutical Industry (Lif) and DANSK BIOTEK highlighting significant growth in the field. Published in 2024, the report showcases multiple Danish strongholds in the development and testing of new drugs, including an increase in clinical trials across all phases and a rising willingness among Danish citizens to participate.
Steady growth in clinical trials and participation
Based on data from the members of the two organisations, the report shows that Denmark hosted 450 active clinical trials in 2023, up from 410 in 2022, thus displaying a huge rise by 40 clinical trials in just one year. The report also shows that for the first time in many years there is an increase in the citizen participation in trials. The number of Danish trial participants grew from 5,822 in 2022, to 6,036 in 2023, underscoring the correlation between Denmark’s clinical trial activity and public engagement.
Over the past few years Denmark has experienced an increase in the number of clinical trials conducted. Clinical trials are crucial for Danish patients and the Danish healthcare system, as it gain new knowledge, and new forms of treatment that benefits the patients. In addition, the trials helps to create new jobs, besides of adding new knowledge and innovation to the Danish healthcare system.
Key insights from the report
Denmark’s clinical trial ecosystem gains recognition
A separate report from IQVIA on the clinical trial ecosystem in Europe, published in 2024, underscores Denmark’s position as one of Europe’s strongest ecosystems for clinical trials. The report concludes that this, amongst others, is based on Denmark taking proactive, cross-stakeholder actions to ensure the country is an attractive location for clinical trials.
The new Danish life science strategy, published at the end of 2024,there is also a great focus on strengthening the conditions for conducting clinical trials in Denmark. One key initiative is the establishment of a fourth scientific ethical committee that will focus on procession applications for phase I trial within 14 days. The aim in the life science strategy is for Denmark to be among the countries in Europa that performs the most clinical trials per capita in the years leading up to 2030.
Denmark’s continuous investment in clinical research, coupled with strong public engagement, ensures that the country remains at the forefront of global medical innovation - offering benefits not only to patients but to the entire healthcare ecosystem.
Download the Danish National Life Sciences strategy here
get in touch
We provide free-of-charge confidential and tailor-made solutions for foreign companies looking to set up a new business in Denmark or expand an existing one. Please contact one of our experts here:
Loading...